These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 2940096)

  • 1. Solubilization and characterization of the 5-hydroxytryptamine transporter complex from rat cerebral cortical membranes.
    Habert E; Graham D; Langer SZ
    Eur J Pharmacol; 1986 Mar; 122(2):197-204. PubMed ID: 2940096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of [3H]paroxetine binding to rat cortical membranes.
    Habert E; Graham D; Tahraoui L; Claustre Y; Langer SZ
    Eur J Pharmacol; 1985 Nov; 118(1-2):107-14. PubMed ID: 2935409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial purification and characterization of the sodium-ion-coupled 5-hydroxytryptamine transporter of rat cerebral cortex.
    Graham D; Esnaud H; Langer SZ
    Biochem J; 1992 Sep; 286 ( Pt 3)(Pt 3):801-5. PubMed ID: 1417739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3H]paroxetine binding to cerebral cortical membranes of the rat.
    Graham D; Tahraoui L; Langer SZ
    Neuropharmacology; 1987 Aug; 26(8):1087-92. PubMed ID: 2958720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of 5-HT3 binding sites in NG108-15, NCB-20 neuroblastoma cells and rat cerebral cortex using [3H]-quipazine and [3H]-GR65630 binding.
    Sharif NA; Wong EH; Loury DN; Stefanich E; Michel AD; Eglen RM; Whiting RL
    Br J Pharmacol; 1991 Apr; 102(4):919-25. PubMed ID: 1830236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization and purification of the neuronal sodium-ion-coupled 5-hydroxytryptamine transporter.
    Graham D; Esnaud H; Langer SZ
    Biochem Soc Trans; 1991 Feb; 19(1):99-102. PubMed ID: 1828051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Partial purification and characterization of the human placental serotonin transporter.
    Ramamoorthy S; Leibach FH; Mahesh VB; Ganapathy V
    Placenta; 1993; 14(4):449-61. PubMed ID: 8248037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A common binding site for tricyclic and nontricyclic 5-hydroxytryptamine uptake inhibitors at the substrate recognition site of the neuronal sodium-dependent 5-hydroxytryptamine transporter.
    Graham D; Esnaud H; Habert E; Langer SZ
    Biochem Pharmacol; 1989 Nov; 38(21):3819-26. PubMed ID: 2532013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The serotonin transporter from human brain: purification and partial characterization.
    Rotondo A; Giannaccini G; Betti L; Chiellini G; Marazziti D; Martin C; Lucacchini A; Cassano GB
    Neurochem Int; 1996 Mar; 28(3):299-307. PubMed ID: 8813248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Solubilization of high-affinity [3H]tryptamine-binding sites from rat brain.
    Brüning G; Rommelspacher H
    Eur J Biochem; 1985 Nov; 153(1):95-9. PubMed ID: 4065152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Solubilization and characterization of [3H]imipramine and [3H]paroxetine binding sites from calf striatum.
    Rotondo A; Giannaccini G; Quattrone C; Marazziti D; Martini C; Cassano GB; Lucacchini A
    Neurochem Res; 1994 Oct; 19(10):1295-300. PubMed ID: 7891847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [125I]5-iodo-6-nitroquipazine: a potent and selective ligand for the 5-hydroxytryptamine uptake complex. I. In vitro studies.
    Mathis CA; Taylor SE; Biegon A; Enas JD
    Brain Res; 1993 Aug; 619(1-2):229-35. PubMed ID: 8374781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. One-step purification of the serotonin transporter located at the human platelet plasma membrane.
    Launay JM; Geoffroy C; Mutel V; Buckle M; Cesura A; Alouf JE; Da Prada M
    J Biol Chem; 1992 Jun; 267(16):11344-51. PubMed ID: 1534559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solubilization and characterization of high-affinity [3H]serotonin binding sites from bovine cortical membranes.
    VandenBerg SR; Allgren RL; Todd RD; Ciaranello RD
    Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3508-12. PubMed ID: 6574495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [3H]paroxetine binding and serotonin content of rat and rabbit cortical areas, hippocampus, neostriatum, ventral mesencephalic tegmentum, and midbrain raphe nuclei region.
    Dewar KM; Reader TA; Grondin L; Descarries L
    Synapse; 1991 Sep; 9(1):14-26. PubMed ID: 1724575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central serotonergic uptake mechanisms in hypertensive rats: effects of clonidine and centhaquin.
    Gulati A; Arora RC; Crayton J
    Eur J Pharmacol; 1993 Feb; 231(2):151-6. PubMed ID: 8453971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lower 3H-paroxetine binding in cerebral cortex of suicide victims is partly due to fewer high affinity, non-transporter sites.
    Mann JJ; Henteleff RA; Lagattuta TF; Perper JA; Li S; Arango V
    J Neural Transm (Vienna); 1996; 103(11):1337-50. PubMed ID: 9013420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sodium dependence of [3H]paroxetine binding and 5-[3H]hydroxytryptamine uptake in rat diencephalon.
    Mann CD; Hrdina PD
    J Neurochem; 1992 Nov; 59(5):1856-61. PubMed ID: 1402927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoradiographic localization of 3H-paroxetine-labeled serotonin uptake sites in rat brain.
    De Souza EB; Kuyatt BL
    Synapse; 1987; 1(5):488-96. PubMed ID: 2975068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of [3H]paroxetine binding by various serotonin uptake inhibitors: structure-activity relationships.
    Marcusson JO; Norinder U; Högberg T; Ross SB
    Eur J Pharmacol; 1992 May; 215(2-3):191-8. PubMed ID: 1396986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.